Prenatal ultrasound findings of rasopathies in a cohort of 424 fetuses: update on genetic testing in the NGS era

Kyra E Stuurman,¹ Marieke Joosten,¹ Ineke van der Burgt,² Mariet Elting,³ Helger G Yntema,² Hanne Meijers-Heijboer,³ Tuula Rinne²

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2018-105746>)

¹Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands

²Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands

³Department of Clinical Genetics, Amsterdam University Medical Center, Amsterdam, the Netherlands

Correspondence to

Dr Tuula Rinne, Department of Human Genetics, Radboud University Medical Center, Nijmegen 6500HB, Netherlands; tuula.rinne@radboudumc.nl

Received 12 September 2018

Revised 14 March 2019

Accepted 24 March 2019

Published Online First 30 April 2019

ABSTRACT

Background This study evaluates 6 years of prenatal rasopathy testing in the Netherlands, updates on previous data and gives recommendations for prenatal rasopathy testing.

Methods 424 fetal samples, sent in for prenatal rasopathy testing in 2011–2016, were collected. Cohort 1 included 231 samples that were sequenced for 1–5 rasopathy genes. Cohort 2 included 193 samples that were analysed with a 14-gene next generation sequencing (NGS) panel. For all mutation-positive samples in both cohorts, the referring physician provided detailed ultrasound findings and postnatal follow-up. For 168 mutation-negative samples in cohort 2, solely clinical information on the requisition form was collected.

Results In total, 40 (likely) pathogenic variants were detected (9.4%). All fetuses showed a variable degree of involvement of prenatal findings: increased nuchal translucency (NT)/cystic hygroma, distended jugular lymph sacs (JLS), hydrops fetalis, polyhydramnios, pleural effusion, ascites, cardiac defects and renal anomalies. An increased NT was the most common finding. Eight fetuses showed solely an increased NT/cystic hygroma, which were all larger than 5.5 mm. Ascites and renal anomalies appeared to be poor predictors of pathogenic outcome.

Conclusion Fetuses with a rasopathy show in general multiple ultrasound findings. The larger the NT and the longer it persists, the more likely it is to find a pathogenic variant. Rasopathy testing is recommended when the fetus shows an isolated increased NT ≥ 5.0 mm or when NT of ≥ 3.5 mm and at least one of the following ultrasound anomalies is present: distended JLS, hydrops fetalis, polyhydramnios, pleural effusion, ascites, cardiac defects and renal anomalies.

INTRODUCTION

Noonan syndrome (MIM: 163950) is characterised by postnatal short stature, distinctive facial features, congenital heart defects, variable degree of developmental delay and other structural abnormalities.¹ The incidence is 1 in 1000–2500 live births.^{2–4} Noonan syndrome and phenotypically overlapping syndromes such as Costello syndrome (MIM: 218040) and cardiofaciocutaneous syndrome (MIM: 115150) are part of the so-called rasopathies and are caused by at least 16 genes (*BRAF* (MIM: 164757), *CBL* (MIM: 165360), *HRAS* (MIM: 190020), *KRAS* (MIM: 190070), *LZTR1* (MIM: 600574), *MAP2K1* (MIM:

176872), *MAP2K2* (MIM: 601263), *NRAS* (MIM: 164790), *PPP1CB* (MIM: 600590), *PTPN11* (MIM: 176876), *RAF1* (MIM: 164760), *RIT1* (MIM: 609591), *SHOC2* (MIM: 602775), *SOS1* (MIM: 182530), *SOS2* (MIM: 601247) and *SPRED1* (MIM: 609291)), the *PTPN11* gene being the most prevalent gene.^{5–6} Prenatal features of rasopathies have long been documented and can include increased nuchal translucency (NT) and/or cystic hygroma, distended jugular lymph sacs (JLS), hydrops fetalis, polyhydramnios, pleural effusion, ascites, cardiac defects and renal anomalies.^{7–12} It has been previously estimated that mutations in the rasopathy genes are found in 6.7%–19% of fetuses with increased NT and additional anomalies on ultrasound.^{10–13} To date, only five studies have systematically evaluated the prenatal phenotype of Noonan syndrome.^{10–12–14–16}

Croonen *et al*¹⁰ performed a detailed study of prenatal diagnostic Noonan syndrome testing in fetuses with abnormal ultrasound findings (including enlarged NT above the 95th percentile, cystic hygroma, distended JLS, ascites, hydrops fetalis, pleural effusion, polyhydramnios, congenital heart disease and renal abnormalities) and showed a 17.3% mutation detection rate. The aim of Croonen's study was to provide a protocol for prenatal Noonan syndrome testing.¹⁰ However, only 1–4 genes (*KRAS*, *PTPN11*, *RAF1*, and *SOS1*) were tested in their diagnostic study group (fetus with normal karyotype and specific abnormal ultrasound findings) and 10 genes (*BRAF*, *HRAS*, *KRAS*, *MAP2K1*, *MAP2K2*, *NRAS*, *PTPN11*, *RAF1*, *SHOC2* and *SOS1*) in their anonymised study group (fetus with normal karyotype and increased NT, cystic hygroma, fetal hydrops and/or cardiac anomalies). Currently, a next generation sequencing (NGS) gene panel of 14 genes is used in the Netherlands in order to detect mutations in both prenatal and postnatal cases suspected of a rasopathy. Recently, a new guideline with regard to prenatal testing of a rasopathy in the presence of an increased NT was implemented in the Netherlands¹⁷; therefore, we considered it of clinical relevance to update on the previously published data.

Additionally, this study focuses on expanding the knowledge of the prenatal phenotype of a rasopathy. We performed a retrospective study in a consecutive series of 193 fetuses at time of diagnostic testing suspected of a rasopathy and another consecutive series of 231 fetuses in which a prenatal NGS panel of 14 genes involved in rasopathies was performed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Stuurman KE, Joosten M, van der Burgt I, *et al.* *J Med Genet* 2019;**56**:654–661.

METHODS

Patients

Included in this study is a consecutive series of 424 prenatally sampled fetuses with one or more of the following ultrasound findings: increased NT/cystic hygroma (defined as NT ≥ 3.5 mm), distended JLS, pleural effusion, ascites, polyhydramnios, cardiac defects and/or renal anomalies and a normal chromosomal microarray result. Cystic hygroma is considered an outdated term and combined with increased NT in this study.¹⁸ The samples were received from the Clinical Genetics departments of all University Medical Centers in the Netherlands and analysed in the Genome diagnostic laboratory of the Radboud University Medical Center in Nijmegen between January 2011 and December 2016. Of these 424 samples, 231 were received and analysed between January 2011 and September 2014 (cohort 1) and 193 between October 2014 and December 2016 (cohort 2). Samples were sent in as cultured or uncultured amniotic fluid sample, chorionic villi sample or DNA extracted from amniotic fluid or chorionic villi samples. In a few samples, DNA from the umbilical cord or fetal fibroblasts after termination of pregnancy was sent in.

Referring clinical geneticists of the mutation positive samples were asked to provide additional details on the clinical prenatal phenotype and postnatal phenotype if available. The mutation negative samples from cohort 2 were analysed only by the clinical information provided on the requisition form by the referring doctor.

DNA analysis

In cohort 1 (231 samples), 1–5 most commonly described rasopathy genes (*BRAF*, *KRAS*, *MAP2K1*, *PTPN11* and/or *RAF1*) were parallel sequenced. All detected (likely) pathogenic variants or variants of uncertain significance were subsequently tested in parents if parental DNA was available.

Cohort 2, consisting of 193 fetal samples, was tested using the NGS rasopathy gene panel. The coding sequences and splice sites of *A2ML1* (MIM: 610627), *BRAF*, *CBL*, *HRAS*, *KRAS*, *MAP2K1*, *MAP2K2*, *NRAS*, *PTPN11*, *RAF1*, *RIT1*, *SHOC2*, *SOS1* and *SPRED1* were sequenced by ion semiconductor sequencing (Ion AmpliSeq™ Noonan panel, ThermoFisher Scientific) combined with Sanger sequencing. All detected (likely) pathogenic variants or variants of uncertain significance were subsequently confirmed by Sanger sequencing and tested in parents if parental samples were available. Five class variant classification system was used: clearly not pathogenic variant (Class 1), unlikely pathogenic variant (Class 2), variant of uncertain clinical significance (Class 3), likely pathogenic variant (Class 4) and clearly pathogenic variant (Class 5).¹⁹

Statistical analysis

The data were analysed in SPSS V.22. For statistical analysis, a χ^2 test, independent t-test, Shapiro-Wilk test, Mann-Whitney U test, logistic regression and descriptive statistics were used. A probability value of less than 0.05 was considered significant.

RESULTS

Total

Over the 6-year period (2011–2016), 44 out of 424 fetuses were found to have a (likely) pathogenic variant or variant of unknown significance in one of the 14 rasopathy genes (10.4%). Forty variants had either been described before and shown to be pathogenic (Class 5) or were likely pathogenic (Class 4) (9.4%). Four variants were first considered variants of unknown significance (Class 3), but after segregation analysis, they were considered as likely benign variants (Class 2) as they were parentally inherited and the

Figure 1 Genes involved in the mutation-positive samples (n=40 (%)).

parent did not show a rasopathy phenotype. These variants were found in the *RAF1*, *RIT1*, *SOS1* and *HRAS* genes. Twenty-seven of the 40 (likely) pathogenic variants were found in the *PTPN11* gene (67.5%). Five fetuses showed a (likely) pathogenic *RAF1* gene variant (12.5%). Three pathogenic variants were seen in the *RIT1* gene (7.5%). In the *BRAF*, *HRAS*, *MAP2K1*, *SHOC2* and *SOS1* genes, a (likely) pathogenic variant was found in one fetus each (2.5% each gene) (figure 1). Thirty-three of 40 (82.5%) (likely) pathogenic variants were *de novo*, two were inherited from an affected mother (5%) and five showed unknown inheritance, because parents were not tested (12.5%).

Cohort 1

For cohort 1, in which 1–5 genes were analysed, 15 (likely) pathogenic variants were found in 231 samples (6.5%). Thirteen (likely) pathogenic variants were found in the *PTPN11* gene (5.6%), one pathogenic variant in the *RAF1* gene (0.4%) and one likely pathogenic variant in the *MAP2K1* gene (0.4%) (table 1).

Cohort 2

For cohort 2, in which a NGS panel of 14 genes was analysed, 25 (likely) pathogenic variants were found in 193 samples (13%). Of the 25 (likely) pathogenic variants, 14 were found in the *PTPN11* gene (7.3%), four were found in the *RAF1* gene (2%) and three

Table 1 Mutation-positive samples

Gene	2011–2016 (n (%))	Cohort 1: 2011–Oct 2014 (1–5 genes) (n (%))	Cohort 2: Oct 2014–2016 (NGS panel) (n (%))
<i>PTPN11</i>	27/424 (6.4)	13/231 (5.6)	14/193 (7.3)
<i>RAF1</i>	5/424 (1.2)	1/231 (0.4)	4/193 (2)
<i>RIT1</i>	3/424 (0.7)	N/A	3/193 (1.6)
<i>SOS1</i>	1/424 (0.2)	N/A	1/193 (0.5)
<i>HRAS</i>	1/424 (0.2)	N/A	1/193 (0.5)
<i>MAP2K1</i>	1/424 (0.2)	1/231 (0.4)	0/193 (0)
<i>BRAF</i>	1/424 (0.2)	0/231 (0)	1/193 (0.5)
<i>SHOC2</i>	1/424 (0.2)	N/A	1/193 (0.5)
<i>KRAS</i>	0/424 (0)	0/231 (0)	0/193 (0)
All other genes in NGS panel	0/424 (0)	N/A	0/193 (0)
Total mutation positive	40/424 (9.4%)	15/231 (6.5%)	25/193 (13%)

N/A, not applicable; NGS, next generation sequencing.

Table 2 Distribution of NT in cohort 2 (mutation-negative versus mutation-positive samples)

NT (mm)	Mutation-negative samples (n=168) (n(%))	Mutation-positive samples (n=25) (n(%))
<3.5	3 (2)	1 (4)
3.5–3.9	25 (15)	2 (8)
4.0–4.9	22 (13)	0 (0)
5.0–5.9	21 (12.5)	1 (4)
6.0–6.9	6 (4)	3 (12)
7.0–7.9	4 (2)	1 (4)
>8.0	10 (6)	11 (44)
Increased, but unknown	21 (12.5)	4 (16)
Nuchal fold at 20 weeks of gestational age	34 (20)	1 (4)
Not measured	22 (13)	1 (4)

NT, nuchal translucency.

were found in the *RIT1* gene (1.5%). One (likely) pathogenic variant was present in four separate samples in the *SOS1*, *HRAS*, *BRAF* and *SHOC2* genes (each gene 0.5%), respectively (table 1).

Two of the 14 pathogenic variants in the *PTPN11* gene were maternally inherited. Both mothers were suspected of having Noonan syndrome when the fetal DNA sample was sent in for rasopathy testing.

Distribution of NT between negative and positive samples in cohort 2

The distributions of NT in cohort 2 were evaluated comparing the mutation-negative and mutation-positive samples (table 2, figures 2 and 3). Tests for normality on samples with measured NT (n=110) showed that mutation-positive samples were normally distributed (mean of 8.46 mm with ± 3.7 SD), while mutation-negative samples were non-normal (median of 4.7 mm with ± 2.0 IQR) where ~50% of mutation-negative samples had an NT <5 mm. As a result, NT thickness in mutation-positive samples was significantly larger compared with mutation-negative samples ($p < 0.001$, $Z = 3.858$).

Clinical findings of all samples in cohort 2

The ultrasound findings of all samples in cohort 2 were analysed according to mutation-positive and mutation-negative samples (table 3). Increased NT/cystic hygroma in the first trimester was

Figure 2 Distribution of nuchal translucency in cohort 2: mutation-negative samples (n=168 (%)).

Figure 3 Distribution of nuchal translucency in cohort 2: mutation-positive samples (n=25 (%)).

the most prevalent finding in all samples (86% of all samples). Although there is a statistically significant difference in the thickness of the NT between the mutation-positive and mutation-negative group, there was no statistic difference in the presence of an increased NT/cystic hygroma between mutation-positive and mutation-negative samples. The ultrasound finding ascites was not statistically more prevalent in the mutation-positive samples. All other ultrasound findings (JLS, hydrops fetalis, pleural effusion, cardiac anomalies, renal abnormalities and polyhydramnios) were statistically more prevalent in the mutation-positive samples (table 3).

Clinical findings in mutation-positive fetuses in cohorts 1 and 2

The 40 pathogenic mutation positive fetuses showed a variable degree of involvement of prenatal findings. Increased NT/cystic hygroma (including persistent NT (defined as NT still visible on ultrasound at 14 weeks of gestation)) was the sole finding in eight fetuses (20.0%). The NTs were between 5.5 and 13 mm for seven samples, whereas one showed oedema around the fetus without exact measurement. Five of these fetuses were terminated at 16 and 22 weeks of gestation, respectively, without autopsy, therefore eliminating follow-up, and one resulted in a premature delivery at

Table 3 Cohort 2: prenatal ultrasound findings in fetuses with normal chromosomal microarray and analysed for rasopathy using next generation sequencing panel

Prenatal findings	Total (n (%))	Mutation positive (n (%))	Mutation negative (n (%))	P-value
Increased NT/cystic hygroma in first trimester*	166/193 (86)	23/25 (92)	143/168 (85)	0.282
Persistent NT	61/193 (32)	16/25 (64)	45/168 (27)	0.000
Jugular lymph sacs	24/193 (12)	12/25 (43)	12/168 (7)	0.000
Hydrops fetalis	26/193 (13)	14/25 (56)	12/168 (7)	0.000
Pleural effusion	32/193 (17)	11/25 (44)	21/168 (13)	0.000
Ascites	8/193 (4)	3/25 (12)	5/168 (3)	0.069
Cardiac anomalies	34/193 (18)	12/25 (48)	22/168 (13)	0.000
Renal anomalies	10/193 (5)	4/25 (16)	6/168 (4)	0.027
Polyhydramnios	7/193 (4)	4/25 (16)	3/168 (2)	0.006
Other anomalies	32/193 (17)	9/25 (36)	23/168 (14)	0.009

*Excluding nuchal fold, which is measured at approximately 20 weeks of gestation. NT, nuchal translucency.

17 weeks of gestation. Two fetuses were life born. In this isolated increased NT group, seven fetuses harboured a pathogenic *PTPN11* variant and one a pathogenic *RIT1* variant. Nine fetuses were shown to have an increased NT/cystic hygroma with one other finding (22.5%): three had JLS, two had hydrops, one had polyhydramnios, one had a cardiac defect, one showed bilateral hydrothorax and one had unilateral clubfoot. Seven fetuses harboured a pathogenic *PTPN11* variant and two a pathogenic *RAF1* variant. The remaining 23 fetuses had at least two or more ultrasound findings (23 out of 40 fetuses, 57.5%) (table 4). Although ductus venosus anomalies have been reported as being associated with Noonan syndrome, we found evidence in only one of the mutation-positive fetuses in our study.^{20–22} This fetus, however, also showed 6 of the specific rasopathy ultrasound features.

All 40 mutation-positive samples were analysed for clinical outcome (table 4). Twenty-eight pregnancies were terminated before 24 weeks of gestation (70%). Two fetuses were born prematurely and died shortly after birth (at 17 and 27 weeks of gestation, respectively)(5%), two pregnancies ended in intrauterine fetal death (5%) and eight pregnancies ended in a term birth (20%). Of these births, one child died during birth, one shortly after birth and one child a few years after birth. Five children with prenatally confirmed Noonan syndrome are still alive (12.5%). There were no significant differences in clinical findings in mutation positive samples cohort 1 versus cohort 2. It was expected that cohort 2 included fetuses with more ultrasound findings due to proposed new criteria by Croonen *et al.*¹⁰ However, not all genetic centres in the Netherlands used these new criteria. Additionally, we did not find a correlation between genotype and phenotype. There were a few recurrent mutations and within those mutations a shared phenotype did not appear to be present. Clinical information about the non-pathogenic variants is provided in the online supplementary table 1.

DISCUSSION

Recently, a new Dutch guideline was implemented with regard to prenatal testing for a rasopathy. This guideline showed that only a handful of studies were informative for rasopathy testing and it therefore was the motivation for this study. We present the largest cohort of prenatally tested samples for rasopathies. In a previous paper by Croonen *et al.*, testing for a rasopathy in pregnancy was recommended when an enlarged NT is present and at least one of the following features: distended JLS, cystic hygroma, hydrops fetalis, hydrothorax, cardiac anomalies, renal anomalies, polyhydramnios and ascites.¹⁰ In this paper, we provide updated recommendations for testing for a rasopathy based on our clinical and genetic findings in a cohort of 424 fetuses.

Mutation detection

In our cohort of 424 fetuses, an overall pathogenic mutation detection rate of 9.4% was found, with a 6.5% mutation detection rate in cohort 1 (testing of 1–5 genes) and 13% in cohort 2 (NGS panel cohort). Croonen *et al.* found a 17.3% mutation rate in their diagnostic group tested for Noonan syndrome. It is unclear what causes the difference in mutation detection rate. The inclusion criteria might play a role, because no isolated enlarged NT was included in their study. However, Croonen *et al.* included cystic hygroma as a separate entity, whereas in our study, these anomalies were combined. If all 58 isolated increased NT samples with NT <5.0 mm had been excluded in our cohort 2, mutation detection in this cohort would have increased to 18.5% (25/135). Additionally, in cohort 1, 1–5 genes were tested, whereas in cohort 2, 14 genes were tested. This latter presumably leads to a higher mutation detection

rate. If in cohort 2 only the five genes from cohort 1 were tested, the percentage of mutation detection in cohort 2 would have been 9.8% compared with 13% with NGS panel. However, not every sample in cohort 1 was tested for five genes. Therefore, the mutation detection percentage in cohort 1 might be an under-representation compared with the same genes tested in cohort 2. The difference in mutation detection between our two cohorts seems to be due to the increased amount of genes tested.

In addition to the Croonen *et al.*'s paper, Ali *et al.* recently published a cohort of 39 fetuses with enlarged NT and normal karyotype which underwent testing for Noonan syndrome.¹⁶ The authors used two laboratories with a selected panel of 11 and 9 genes, respectively. They found a mutation percentage of approximately 10%. This is the approximately same percentage as we found in our much larger total cohort. However, in our cohort 2 we found a slightly higher mutation detection of 13%. This might be due to the fact that the *RIT1* gene was not present in one of the panels used by Ali *et al.* The *RIT1* gene is an important gene in our cohort, with three of the 25 mutations (12%) found in cohort 2 being in this gene. Additionally, microdeletions/duplications were not tested by Ali *et al.*, which have been filtered out in our cohorts.

More than 80% of our mutation-positive samples were *de novo*. In literature, the *de novo* rate has been estimated at 30%–75%.^{6,23,24} Our cases were prenatally detected and the higher percentage could be explained by the fact that milder cases might not show a prenatal phenotype and therefore are not tested in pregnancy. As well, hydropic fetuses have not always been tested for a rasopathy, which would then be missed out on *de novo* mutation detection.

Genes

In cohorts 1 and 2 combined only eight genes were involved in prenatally confirmed Noonan syndrome. Although no pathogenic variants were found in the *A2ML1*, *CBL*, *MAP2K1*, *NRAS*, *SPRED1* and *KRAS* genes in our total cohort, in literature a prenatal phenotype has been described for all these genes, except for the *SPRED1* gene. For the *A2ML1* gene, however, only one report has been published and it is debatable whether this gene is involved in the rasopathies.^{10,15,25–27}

Overall, the *PTPN11* gene is prenatally and postnatally the most prevalent gene in the panel; 67.5% of our samples with a rasopathy have a pathogenic *PTPN11* variant, which is in agreement with literature.^{5,6,28}

In our study, *RAF1* and *RIT1* are the most frequently described genes involved in rasopathies after the *PTPN11* gene. *RIT1* has relatively recently been discovered and it also has an important role in prenatal rasopathies. This is possibly due to the presence of lymphatic malformations in this gene,²⁹ which is easily recognisable on fetal ultrasound. In our study, all three fetuses with a pathogenic *RIT1* mutation showed lymphatic problems. However, the indication of sending in samples for testing was increased NT or associated lymphatic problem; therefore, there is a bias in our cohort regarding this ultrasound feature. Only one of the three fetuses with a pathogenic *RIT1* variant in our cohort showed a cardiac defect. This is not significantly more than the fetuses with other pathogenic variants. Cardiac anomalies are frequently documented in patients with a pathogenic *RIT1* mutation.^{29,30} However, pulmonic valve stenosis and hypertrophic cardiomyopathy, the common cardiac defects described in Noonan syndrome, are difficult to visualise on fetal ultrasound. Therefore, they are easily overlooked in pregnancy and might not be confined to only fetuses with a *RIT1* mutation. *SOS1* has to our knowledge only been described a handful of times before in the prenatal setting,¹⁵ and in our study only one fetus showed a pathogenic variant. This

Table 4 Mutation-positive samples (cohorts 1 and 2) and the detected ultrasound findings

Case	Gene	Genomic change	Protein change	NGS panel	De novo	Pathogenicity	NT (mm)	Persistent NT	JLS	Hydrops fetalis	Pleural effusion	Ascites	Cardiac anomalies	Renal anomalies	Polyhydramnios	Other anomalies	Pregnancy outcome
1	PTPN11	c.124A>G	Thr42Ala	+	?	P	Oedema around fetus at 10 weeks	+	—	—	—	—	—	—	—	—	Live birth, deceased at age 2
2	PTPN11	c.179G>T	Gly60Val	+	+	P	8.6	+	+	+	+	—	Pericardial effusion, DORV	—	—	Lemon-shaped head	ToP
3	PTPN11	c.179G>T	Gly60Val	+	+	P	8.9	+	+	—	—	—	AVSD	—	—	Abnormal skull	ToP at 21 weeks
4	PTPN11	c.182A>G	Asp61Gly	+	?	P	Oedema around fetus at 11 weeks	+	+	+	—	—	AVSD, hypoplastic left heart	Pyelectasis	—	—	ToP
5	PTPN11	c.184T>G	Tyr62Asp	—	+	P	6.1	—	—	—	—	—	—	—	Mild 34 weeks	—	Live birth
6	PTPN11	c.184T>G	Tyr62Asp	—	+	P	11.0	+	—	—	—	—	—	—	—	—	ToP
7	PTPN11	c.184T>G	Tyr62Asp	+	+	P	9.8	—	—	+	+	—	—	—	—	—	ToP at 16 weeks
8	PTPN11	c.213T>G	Phe71Leu	+	+	LP	Increased	+	—	+	—	—	—	—	—	—	ToP at 14 weeks
9	PTPN11	c.214G>T	Ala72Ser	—	+	P	9.3	+	+	—	—	—	Hypoplastic right heart, small tricuspid valve	—	—	—	ToP at 23 weeks
10	PTPN11	c.214G>C	Ala72Pro	+	+	LP	8.1	+	—	+	+	—	—	—	—	—	ToP
11	PTPN11	c.215C>T	Ala72Val	—	+	LP	7.0	—	—	—	—	—	—	—	—	—	ToP at 16 weeks
12	PTPN11	c.228G>T	Glu76Asp	—	—	mat	5.7	—	—	—	—	—	AVSD, hypoplastic left heart	—	—	—	ToP at 21 weeks
13	PTPN11	c.417G>C	Glu139Asp	+	+	P	6.0	+	—	+	+	—	—	—	—	—	ToP at 17 weeks
14	PTPN11	c.767A>G	Gln256Arg	+	?	P	3.8	—	+	—	—	—	—	—	—	—	Live birth
15	PTPN11	c.794G>A	Arg265Gln	—	+	P	6.0	—	—	—	—	—	—	—	—	—	Live birth
16	PTPN11	c.854T>C	Phe285Ser	—	+	P	8.7	+	+	+	+	+	Pericardial effusion	Mild pyelectasis	—	Lemon-shaped head	ToP at 23 weeks
17	PTPN11	c.854T>C	Phe285Ser	—	+	P	7.7	+	+	—	+	Very mild	—	—	+27 weeks	Low set ears	Live birth at 27 weeks, postnatal death
18	PTPN11	c.854T>C	Phe285Ser	+	+	P	Increased	+	+	—	—	—	PS	—	+	—	ToP
19	PTPN11	c.922A>G	Asn308Asp	—	+	P	5.5	—	—	—	—	—	—	—	—	—	ToP at 22 weeks
20	PTPN11	c.922A>G	Asn308Asp	+	+	P	13.0	+	—	—	—	—	—	—	—	—	ToP >20 weeks
21	PTPN11	c.922A>G	Asn308Asp	+	+	P	9.6	+	—	—	—	—	—	—	—	—	Premature delivery at 17 weeks
22	PTPN11	c.1381G>A	Ala461Thr	—	+	P	9.2	—	+	+	+	+	Fibrous VSD	Horse shoe kidney	—	Malrotation bowel, ambiguous genitalia	IUFD at 17 weeks
23	PTPN11	c.1403C>T	Thr468Met	—	+	P	>3.5	—	+	—	—	—	—	—	—	—	ToP at 22 weeks
24	PTPN11	c.1403C>T	Thr468Met	+	—	mat	8.0	—	+	—	—	—	—	—	—	—	Live birth
25	PTPN11	c.1504T>G	Ser502Ala	+	?	P	13.7	+	+	+	—	—	AVSD	Pyelectasis	—	Absent ductus venosus, dysmorphic facial features	ToP
26	PTPN11	c.1507G>C	Gly503Arg	+	+	P	3.6	—	—	—	+bilat	—	—	—	—	—	ToP at 24 weeks
27	PTPN11	c.1530G>C	Gln510His	+	+	P	12.0	+	+	+	+	+	Cardiomyopathy, dysplastic mitral valve	Pyelectasis	+	Brachycephaly, hepatomegaly, hypertelorism, large tongue, non-rotation bowel	IUFD at 31 weeks
28	RAF1	c.770C>T	Ser257Leu	+	+	P	8.2	n/a	—	+	—	—	—	—	—	—	ToP at 12 weeks
29	RAF1	c.770C>T	Ser257Leu	+	+	P	5.5	+	+	—	—	—	VSD	—	—	SUA	ToP at 20 weeks

Continued

Table 4 Continued

Case	Gene	Genomic change	Protein change	NGS panel	De novo	Pathogenicity	NT (mm)	Persistent NT	JLS	Hydrops fetalis	Pleural effusion	Ascites	Cardiac anomalies	Renal anomalies	Polyhydramnios	Other anomalies	Pregnancy outcome
30	RAF1	c.770C>T	Ser257Leu	+	+	P	6.9	–	–	+	+	–	–	–	–	–	ToP at 19 weeks
31	RAF1	c.778A>C	Thr260Pro	+	+	LP	6.5	+	–	+	+	–	Hypertrophic myocardium, PS	–	+	Echogenic bowel	Live birth, postnatal death
32	RAF1	c.782C>G	Pro261Arg	+	+	P	8.0	+	–	–	–	–	–	–	–	Unilateral clubfoot	ToP at 16 weeks
33	RIT1	c.319A>G	Met107Val	+	+	P	Nuchal fold at 19 weeks	?	+	+	+	+	–	Pyelectasis	+	–	Died during child birth
34	RIT1	c.319A>G	Met107Val	+	?	P	7.3	+	–	–	–	–	–	–	–	–	ToP
35	RIT1	c.319A>G	Met107Val	+	+	P	18.0	–	–	+	+	+	Hypoplastic right ventricle, tricuspid atresia, pulmonary atresia, VSD	–	–	Low set ears	ToP at 14 weeks
36	MAP2K1	c.383G>A	Gly128Asp	–	+	LP	Increased	+	–	+	+	–	–	–	–	–	ToP at 18 weeks
37	SHOC2	c.4A>G	Ser2Gly	+	+	P	Nuchal fold at 21 weeks	+	–	+	+	–	Cardiomegaly, RV hypertrophy	–	+	Ventriculomegaly	Live birth at 37 weeks
38	BRAF	c.1391G>T	Gly464Val	+	+	LP	11.8	n/a	+	–	–	–	ToF, abnormal ductus venosus, abnormal a. hepatica	–	–	–	ToP at 13 weeks
39	SOS1	c.806T>L>G	Met269Arg	+	+	P	Oedema around fetus	–	+	–	–	–	–	–	–	Macrocephaly, SUA	ToP at 18 weeks
40	HRAS	c.38G>A	Gly134Asp	+	+	P	3.4	+	+	+	+	–	VSD	Hydronephrosis	+	–	ToP at 24 weeks

AVSD, atrioventricular septum defect; DORV, double outlet right ventricle; IUFD, intrauterine fetal death; JLS, jugular lymph sacs; LP, likely pathogenic; NT, nuchal translucency; P, pathogenic; PS, pulmonary stenosis; RV, right ventricle; SUA, single umbilical artery; ToF, termination of pregnancy; VSD, ventricular septum defect; bilat, bilateral; mat, maternal; n/a, not applicable.

is possibly due to a milder phenotype, which might not be recognisable on prenatal ultrasound.

Clinical differences between the mutation-negative and mutation-positive group

The prenatal features persistent increased NT, JLS, hydrops fetalis, pleural effusion, cardiac anomalies and polyhydramnios are significantly more present in fetuses with confirmed rasopathy versus fetuses without a confirmed diagnosis. In both the mutation-positive and mutation-negative groups, an increased NT was the most frequent finding on ultrasound, and there was no significant difference between the groups (p-value 0.282). This is due to the fact that in most instances the indication for prenatal testing of a rasopathy was an increased NT. Therefore, it is difficult to confirm if most prenatal rasopathy cases have indeed an enlarged NT. Ascites is not very specific for fetuses with a rasopathy with a p-value of 0.069. Renal anomalies are significantly more present in mutation-positive samples, but it is not a strong predictor (p-value 0.027). Both ascites and renal anomalies are always seen in combination with hydrops fetalis in our mutation-positive and mutation-negative cohort. Additionally, ascites is only detected in a small amount of mutation-positive and mutation-negative fetuses. The most common renal anomaly is pyelectasis. Although pleural effusion is significantly more present in fetuses with a confirmed rasopathy, this feature on its own does not predict a mutation. We did not find mutations in fetus with solely pleural effusion. Pleural effusion is almost always part of hydrops fetalis (tables 3 and 4).

Clinical findings in the mutation-positive group

In the mutation-positive group, there were eight fetuses (20.0%) with just an isolated NT and only two of these fetuses turned into a term life birth. The other fetuses were terminated before 22 weeks of gestation. It is therefore difficult to determine whether these fetuses would have developed more anomalies in due course of the pregnancy. Twenty-three fetuses showed two or more ultrasound findings additional to the increased NT. Thus, the majority of samples with a confirmed rasopathy (23 of 40 fetuses, 57.5%) have multiple anomalies on ultrasound. We therefore recommend testing for a prenatal rasopathy when the NT is ≥ 3.5 mm and one of the following ultrasound anomalies is present: JLS, hydrops fetalis, pleural effusion, cardiac anomalies, polyhydramnios. It is debatable whether to test for a rasopathy when an enlarged NT is seen in combination with solely ascites or renal anomalies. The chance of finding a pathogenic variant is low, but not excluded.

A rasopathy cannot be excluded when only one ultrasound anomaly is seen, as our study shows pathogenic variants in eight fetuses with an isolated increased NT (with or without persistent NT enlargement). This has been described before.¹⁵ The NTs of the fetuses were, however, large (5.5–13.0 mm). There is a statistical significant difference of the thickness of the NT between the mutation-positive versus the mutation-negative samples with a cut-off at 5.0 mm. Therefore, we recommend testing for prenatal rasopathy in fetuses with an isolated increased NT of ≥ 5.0 mm. Additionally, in the presence of other ultrasound anomalies, the NT tends to be larger as well (online supplementary file 1), which has been described before.¹⁶ Sixteen of the 40 fetuses (40%) with confirmed rasopathy had a cardiac defect. In literature, postnatally, approximately 80% of patients with established rasopathy show a cardiac anomaly.³¹ The difference is most likely due to the fact that the two most common heart defects in a rasopathy, pulmonic valve stenosis and hypertrophic cardiomyopathy, are difficult to detect on prenatal ultrasound. One fetus with a confirmed pathogenic *HRAS* variant had a NT of 3.4 mm. This is technically not

an increased NT. However, this fetus showed multiple other ultrasound anomalies, fitting the prenatal phenotype of a rasopathy. Prenatal testing for a rasopathy when an increased NT is absent should be based on the remaining ultrasound anomalies. One can consider testing for rasopathies when multiple anomalies described in this study are present.

A genotype–phenotype correlation could not be established in our cohort. This might be due to the fact that many pregnancies, some at early gestation, were terminated when a mutation was found and therefore a complete prenatal and postnatal phenotype is lacking. The high percentage of pregnancy terminations (80%) in the mutation-positive group can have several reasons. An important reason might be that parents, who, due to cultural or religious beliefs, would not terminate a pregnancy in the first place, might not opt for genetic testing. Therefore, this could cause a bias in the percentage in termination of pregnancy. Another reason might be poor prognosis and parental anxiety either due to the enlarged NT or due to the combination of several ultrasound findings. For this reason, however, one would expect also a high percentage in termination of pregnancy irrespective of the presence of a mutation in a rasopathy gene. Unfortunately, we did not follow-up on the mutation-negative samples in our cohort. All parents were counselled by clinical geneticists, and in our opinion, a clinical geneticist is the expert physician for counselling a prenatal rasopathy. Parents will then be able to make a well-informed decision.

Several studies have documented a range of 21%–50% prenatal phenotype in patients with a postnatally confirmed rasopathy. These studies also showed a lack of an association between prenatal severity and postnatal outcome.^{12 32}

Challenges

The requisition forms for cohort 1 were not digitally available. As a result, we did not research the clinical phenotype of the mutation-negative samples in this cohort. In cohort 2, the requisition forms were digitally available and we based the prenatal phenotype on what the referring physician had written down. We trusted the information on the requisition form for the mutation-negative samples to be complete.

Our study did not include newborns with Noonan syndrome or an associated disorder. Additionally, a high percentage of terminations of pregnancy in our cohorts was established, which made postnatal follow-up impossible. Therefore, a complete genotype–phenotype correlation can not be made. Additional research about the postnatal phenotype combined with the prenatal phenotype needs to be performed. Finally, the upcoming use of non-invasive prenatal testing (NIPT) presumably decreases the request for prenatal rasopathy testing as increased NT is an important ultrasound finding in the prenatal rasopathies, which is not measured anymore when performing NIPT.

Recommendations

This study is the most extensive study to date involving the largest cohort of prenatally tested rasopathy. We conclude that all but one confirmed prenatal cases of rasopathy show an enlarged NT. We recommend testing of fetuses with solely an increased NT after chromosomal abnormalities have been excluded when the NT is ≥ 5.0 mm. We also recommend testing when the NT is ≥ 3.5 mm and at least one of the following anomalies is present: distended JLS, hydrops fetalis, polyhydramnios, pleural effusion and cardiac defects. Ascites and to a lesser degree renal anomalies in combination with an increased NT are poor predictors to find a pathogenic variant and testing is then debatable. Research for better

correlation between prenatal and postnatal phenotype should be performed.

In general, an NGS panel of known rasopathy genes should be used when a rasopathy is suspected. Although we did not find pathogenic variants in every gene in the panel, in all genes, a prenatal phenotype has been documented in literature. Therefore, a smaller panel is not advisable. However, in countries where an extensive panel is not available, testing for only *PTPN11* gene would catch of at least 50% of the fetuses with a rasopathy.

We assume that adding recently discovered rasopathy genes (*PPP1CB*, *SOS2* and *LZTR1* genes) to the panel would increase the detection rate.

Acknowledgements The authors would like to thank all referring physicians for their detailed information: Katelijne Bouman, Merel van Maarle, Klaske Lichtenbelt, Karin Diderich, Nicolette den Hollander, Laura van Loon, Gretel Oudesluijs, Anja Kattentidt, Wendy van Zelst-Stams, Marjolein Willemsen, Yvonne Arens, Lutgarde Govaerts, Alexa Vermeer, Chantal Kerkhofs, Floor Duijkers, Emilia Bijlsma, Sonja de Munnik.

Contributors Conceptualization: KES and TR. Formal analysis: KES. Investigation: KES and TR. Writing - original draft preparation: KES. Writing - review and editing: KES, TR, MJ, HME, MWE, lvdB, HY.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. *Am J Dis Child* 1968;116:373–80.
- Allanson JE. Noonan syndrome. *J Med Genet* 1987;24:9–13.
- Sharland M, Burch M, McKenna WM, Paton MA. A clinical study of Noonan syndrome. *Arch Dis Child* 1992;67:178–83.
- Nora JJ, Nora AH, Sinha AK, Spangler RD, Lubs HA. The Ullrich-Noonan syndrome (Turner phenotype). *Arch Pediatr Adolesc Med* 1974;127:48–55.
- Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in *PTPN11*, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet* 2001;29:465–8.
- Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD. *PTPN11* mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. *Am J Hum Genet* 2002;70:1555–63.
- Witt DR, Hoyme HE, Zonana J, Manchester DK, Fryns JP, Stevenson JG, Curry CJ, Hall JG. Lymphedema in Noonan syndrome: clues to pathogenesis and prenatal diagnosis and review of the literature. *Am J Med Genet* 1987;27:841–56.
- Benacerraf BR, Greene MF, Holmes LB. The prenatal sonographic features of Noonan's syndrome. *J Ultrasound Med* 1989;8:59–63.
- Nisbet DL, Griffin DR, Chitty LS. Prenatal features of Noonan syndrome. *Prenat Diagn* 1999;19:642–7.
- Croonen EA, Nillesen WM, Stuurman KE, Oudesluijs G, van de Laar IMBM, Martens L, Ockeloen C, Mathijssen IB, Schepens M, Ruiterkamp-Versteeg M, Scheffer H, Faas BHW, van der Burgt I, Yntema HG. Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. *Eur J Hum Genet* 2013;21:936–42.
- Bakker M, Pakjrt E, Bilardo CM. Increased nuchal translucency with normal karyotype and anomaly scan: what next? *Best Pract Res Clin Obstet Gynaecol* 2014;28:355–66.
- Baldassarre G, Mussa A, Dotta A, Banaudi E, Forzano S, Marinosci A, Rossi C, Tartaglia M, Silengo M, Ferrero GB. Prenatal features of Noonan syndrome: prevalence and prognostic value. *Prenat Diagn* 2011;31:949–54.
- Pergament E, Alamillo C, Sak K, Fiddler M. Genetic assessment following increased nuchal translucency and normal karyotype. *Prenat Diagn* 2011;31:307–10.
- Achiron R, Heggesh J, Grisaru D, Goldman B, Lipitz S, Yagel S, Frydman M. Noonan syndrome: a cryptic condition in early gestation. *Am J Med Genet* 2000;92:159–65.
- Hakami F, Dillon MW, Lebo M, Mason-Suares H. Retrospective study of prenatal ultrasound findings in newborns with a Noonan spectrum disorder. *Prenat Diagn* 2016;36:418–23.
- Ali MM, Chasen ST, Norton ME. Testing for Noonan syndrome after increased nuchal translucency. *Prenat Diagn* 2017;37:750–3.
- Stuurman KE, 2017. Available: https://richtlijndatabase.nl/richtlijn/genetische_diagnostiek_bij_echoafwijkingen/verdict_nuchal_translucency_noonan-syndroom.html
- Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH. Cystic hygromas, nuchal edema, and nuchal translucency at 11–14 weeks of gestation. *Obstet Gynecol* 2006;107:678–83.
- Bell J, Bodmer D, Sistermans E, Ramsden S. Practice guidelines for the interpretation and reporting of unclassified variants (uvs) in clinical molecular genetics. *Cmgs/vkgi* 2007.
- Demirci O, Yavuz T, Arisoy R, Pekin O, Acar H, Aydin H, Cetinkaya A, Karaman A, Erdoğan E, Kumru P. Agensis of the ductus venosus – a case with Noonan syndrome. *Genet Couns* 2015;26:373–6.
- Staboulidou I, Pereira S, Cruz JdeJ, Syngelaki A, Nicolaides KH. Prevalence and outcome of absence of ductus venosus at 11(+0) to 13(+6) weeks. *Fetal Diagn Ther* 2011;30:35–40.
- Vigneswaran TV, Homfray T, Allan LD, Simpson JM, Zidere V. Persistently elevated nuchal translucency and the fetal heart. *J Matern Fetal Neonatal Med* 2018;31:2376–80.
- Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, Maier EM, Tartaglia M, Noordam K, van der Burgt I, Burgt vander I. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. *Am J Med Genet A* 2005;134A:165–70.
- Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze H-U, Doerr H-G, Hofbeck M, Singer H, Reis A, Rauch A. Genotype-phenotype correlations in Noonan syndrome. *J Pediatr* 2004;144:368–74.
- Visser LELM, Bonetti M, Paardekooper Overman J, Nillesen WM, Frants SGM, de Ligt J, Zampino G, Justino A, Machado JC, Schepens M, Brunner HG, Veltman JA, Scheffer H, Gros P, Costa JL, Tartaglia M, van der Burgt I, Yntema HG, den Hertog J. Heterozygous germline mutations in *A2ML1* are associated with a disorder clinically related to Noonan syndrome. *Eur J Hum Genet* 2015;23:317–24.
- Bülöw L, Lissewski C, Bressel R, Rauch A, Stark Z, Zenker M, Bartsch O, Hydrops BO. Hydrops, fetal pleural effusions and chylothorax in three patients with *Cbl* mutations. *Am J Med Genet A* 2015;167A:394–9.
- Wong Ramsey KN, Loichinger MH, Slavin TP, Kuo S, Seaver LH. The perinatal presentation of cardiofaciocutaneous syndrome. *Am J Med Genet A* 2014;164A:2036–42.
- Maheshwari M, Belmont J, Fernbach S, Ho T, Molinari L, Yakub I, Yu F, Combes A, Towbin J, Craig WJ, Gibbs R. *PTPN11* mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13. *Hum Mutat* 2002;20:298–304.
- Kouz K, Lissewski C, Spranger S, Mitter D, Riess A, Lopez-Gonzalez V, Lüttgen S, Aydin H, von Deimling F, Evers C, Hahn A, Hempel M, Issa U, Kahlert A-K, Lieb A, Villavicencio-Lorini P, Ballesta-Martinez MJ, Nampoothiri S, Owens-Raeder A, Puchmajerová A, Satanovskij R, Seidel H, Unkelbach S, Zabel B, Kutsche K, Zenker M. Genotype and phenotype in patients with Noonan syndrome and a *RIT1* mutation. *Genet Med* 2016;18:1226–34.
- Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, Hoshika T, Barnett C, Ohashi H, Kawame H, Hasegawa T, Okutani T, Nagashima T, Hasegawa S, Funayama R, Nagashima T, Nakayama K, Inoue S-I, Watanabe Y, Ogura T, Matsubara Y. Gain-of-function mutations in *RIT1* cause Noonan syndrome, a Ras/MAPK pathway syndrome. *Am J Hum Genet* 2013;93:173–80.
- Calcagni G, Limongelli G, D'Ambrosio A, Gesualdo F, Digilio MC, Baban A, Albanese SB, Versacci P, De Luca E, Ferrero GB, Baldassarre G, Agnoletti G, Banaudi E, Marek J, Kaski JP, Tuo G, Russo MG, Pacileo G, Milanesi O, Messina D, Marasini M, Cairello F, Formigari R, Brighenti M, Dallapiccola B, Tartaglia M, Marino B, defects C. Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. *Int J Cardiol* 2017;245:92–8.
- Gaudineau A, Doray B, Schaefer E, Sananès N, Fritz G, Kohler M, Alembik Y, Viville B, Favre R, Langer B. Postnatal phenotype according to prenatal ultrasound features of Noonan syndrome: a retrospective study of 28 cases. *Prenat Diagn* 2013;33:238–41.